Glutamate Decarboxylase 1 (GAD1, also known as GAD67) catalyzes the rate-limiting conversion of L-glutamate to gamma-aminobutyric acid (GABA), the primary inhibitory neurotransmitter in the central nervous system. Beyond its established role in neurological disorders such as Parkinson's disease, schizophrenia, and Stiff-Person Syndrome (SPS), emerging clinical evidence highlights GAD1 as a metabolic and microenvironmental regulator in various cancers, including pancreatic and prostate malignancies. Developing therapeutics targeting GAD1 requires precise enzymatic modulation, isoform selectivity, and robust cellular validation systems.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for GAD1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | GAD1 Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Theoretical MW optimized for enzymatic assay stability. |
View GAD1 Products |
| Gene Delivery | GAD1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines, avoiding transient transfection variance in functional assays. |
View GAD1 Products |
| Benchmark Ab | Anti-GAD1 Recombinant Antibody Recombinant positive control for assay benchmarking, ELISA, and Western Blot validation. |
View GAD1 Products |
| Validator | GAD1 siRNA Set For target knockdown verification and target specificity control. |
View GAD1 Products |
| Related Target A | GAD2 (GAD65) Isoform selectivity screening is critical; GAD2 shares 65% sequence identity but differs in subcellular localization. |
View GAD2 Products |
| Related Target B | GABRA1 Downstream GABA-A receptor subunit alpha-1 to evaluate pathway activation and signaling cascade. |
View GABRA1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isoform Cross-Reactivity (GAD1 vs GAD2) | High-purity human GAD1 and GAD2 recombinant proteins available for parallel selectivity profiling. |
| Assay Interference & Denaturation | Sequence Verified, endotoxin-controlled proteins with optimized buffer systems to preserve native enzymatic conformation. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies and recombinant positive controls included. |
| False Positives in Small Molecule Screens | Validated GAD1 siRNA sets included for target knockdown and specificity confirmation. |
Live GAD1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of GAD1 is expanding along two distinct clinical axes. In neurology, gene therapy approaches (such as AAV-mediated GAD1 delivery) aim to restore GABAergic inhibition in localized brain regions to treat Parkinson's disease and refractory epilepsy. In oncology, small-molecule inhibitors of GAD1 are being explored to disrupt GABA-mediated autocrine loops that promote tumor cell proliferation and immune evasion. As clinical trials progress, achieving absolute selectivity over the highly homologous GAD2 isoform remains a primary safety and efficacy milestone.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Gene Therapy (AAV) | MeiraGTx, Neurologix | Parkinson's Disease, Epilepsy | In vitro expression validation (Need GAD1 Lentivirus for stable cell line generation) |
| Small Molecule Inhibitor | Academic Institutes, Biotech Startups | Pancreatic Cancer, Solid Tumors | Enzymatic selectivity assays (Need High-Purity GAD1 vs GAD2 proteins) |
| Immunotherapy / Diagnostics | Clinical Diagnostic Developers | Stiff-Person Syndrome, Autoimmune Diabetes | Autoantibody binding assays (Need native glycosylated, sequence-verified proteins) |